皮膚科治療薬の世界市場予測2016-2026

◆英語タイトル:Dermatological Drugs Market Forecast 2016-2026
◆商品コード:VGAIN81920
◆発行会社(調査会社):visiongain
◆発行日:2016年7月
◆ページ数:273
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥283,858見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、皮膚科治療薬の世界市場について調査・分析し、皮膚科治療薬の世界市場規模、市場動向、市場予測、市場環境分析、専門家の見解、関連企業情報などを含め、以下の構成でお届けいたします。
1. レポート概要

2. 皮膚科治療薬の概要

3. 皮膚科治療薬の世界市場

4. 乾癬治療薬市場:市場分析・予測

5. 皮膚感染治療薬市場:市場分析・予測

6. にきび治療薬市場:市場分析・予測

7. 皮膚炎治療薬市場:市場分析・予測

8. 皮膚科治療薬の主要国市場

9. 皮膚科治療薬市場における主要企業

10. 皮膚科治療薬:研究開発パイプライン

11. 皮膚科治療薬市場の定性分析

12. 結論

13. 用語集
【レポートの概要】

What can be expected from the Dermatological Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 273-page report provides 208 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the dermatological drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Dermatological Drugs submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the dermatological drugs market including:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• EU5 – Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Dermatological Drugs Market will reach $39.26bn in 2026. We predict a high revenue growth over the forecast period driven by an aging population, increasing patient expectations and a higher incidence of skin conditions, rapid growth of emerging economies and emerging dermatological drug technologies.

Our work analyses the key companies in the market. See visiongain’s analysis of six leading companies, including these:
• Galderma (Nestle Skin Health)
• Johnson & Johnson
• AbbVie
• GlaxosmithKline
• Pfizer
• LEO Pharma

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the dermatological drugs industry?
Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories
• Biosimilar approvals

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma
In summary, our 273-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Dermatological Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading dermatological drugs in the following areas: psoriasis, skin infections, acne and dermatitis.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the dermatological drugs market – discover prospects for leading dermatological drugs: Humira, Stelara, Enbrel, Remicade Taltz, Otezla, Cosentyx, Cubicin, Zyvox, Valtrex, Canesten, Lamisil, Bactroban, Solodyn, Epiduo, Claravis, Aczone, Differin, Abscorical/Epirus, Ziana, Doryx, Bepanthen/Bepanthol, Protopic, Dermovate and Elocon.
• Revenue forecasts to 2026 for eleven leading national market and one leading regional markets – US, EU5, China, Japan, India, Russia, and Braz.
• Assessment of six leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

【レポートの目次】

1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. An Introduction to Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction to Dermatology
2.2.1 The Structure of Skin, Hair, and Nails
2.2.2 Hair and Nails
2.2.3 Sweat and Sebaceous Glands
2.2.4 Functions of the Skin
2.3 Common Skin Diseases
2.3.1 Acne: The Most Common Skin Disease
2.3.1.1 Acne: Epidemiology
2.3.1.2 Acne: Causes and Pathogenesis
2.3.1.3 Acne: Treatment
2.3.2 Dermatitis: Inflammation of the Skin
2.3.2.1 Atopic Dermatitis
2.3.2.2 Contact Dermatitis
2.3.2.3 Seborrhoeic Dermatitis
2.3.2.4 Nummular Dermatitis
2.3.2.5 Perioral Dermatitis
2.3.3 Psoriasis: A Complex Multi-factorial Disease
2.3.4 Rosacea: Vascular Instability
2.3.5 Alopecia: Excessive Shedding Of Hair
2.4 Skin Infections: A Serious Healthcare Threat
2.4.1 Bacterial Skin Infections
2.4.2 Fungal Skin Infections
2.4.3 Viral Skin Infections
2.5 Common Skin Treatments
2.5.1 Creams and Semisolid Emulsions
2.5.2 Ointments
2.5.3 Lotions
2.5.4 Solutions
2.5.5 Occlusive Therapy
2.5.6 Cleansing Agents
2.5.7 Powders and Hydrophilic Polymer
2.5.8 Anti-Infective Agents
2.5.9 Anti-Inflammatory Agents
2.6 Phases of Clinical Trials
2.7 Dermatological Drugs: Market Definition in this Report

3. The Global Dermatological Drugs Market, 2016-2026
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation of the Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market in 2015
3.4 The Global Dermatological Drugs Market: Market Forecast 2016-2026
3.5 Dermatological Drugs: Changing Market Shares by Sector 2016-2026

4. The Psoriasis Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Psoriasis Treatments: The Dominance of Biologics
4.1.1 Leading Products in the Psoriasis Drugs Market, 2015
4.2 Psoriasis: Market Trends and Developments, 2016
4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
4.2.3 The Disadvantages of Biologics in Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2016-2026
4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2015-2026
4.4 Leading Drugs Used in the Treatment of Psoriasis
4.4.1 Humira (adalimumab) – AbbVie
4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
4.4.1.2 Humira: Sales Forecast 2016-2026
4.4.1.3 Future Prospects for Biosimilar Versions of Humira
4.4.2 Stelara (ustekinumab) – Johnson & Johnson
4.4.2.1 Stelara: Historical Sales Analysis, 2010-2014
4.4.2.2 Stelara: Sales Forecast 2016-2026
4.4.2.3 Intensifying Competition for Stelara
4.4.3 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2015
4.4.3.2 Enbrel: Patent Expiries and Potential Competition, 2016-2026
4.4.3.4 Enbrel: Sales Forecast 2016-2026
4.4.3.5 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
4.4.3.6 Competition from Other Drugs
4.4.3.7 Biosimilar Competition for Enbrel
4.4.4 Remicade (infliximab) – Johnson & Johnson
4.4.4.1 Remicade: Historical Sales Analysis, 2010-2015
4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2016-2026
4.4.4.3 Remicade: Sales Forecast 2016-2026
4.4.5 Taltz (ixekizumab) – Eli Lily
4.4.5.1 Taltz: Sales Forecast 2016-2026
4.4.6 Otezla (apremilast) – Celgene
4.4.6.1 Otezla: Sales Forecast 2016-2026
4.4.7 Cosentyx (secukinumab) – Novartis
4.4.7.1 Cosentyx: Sales Forecast 2016-2026
4.4.8 Other Psoriasis Drugs
4.4.8.1 Cimzia (certolizumab) – UCB
4.4.8.2 Sorilux (calcipotriene foam) – GSK
4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2016-2026
4.5 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis and Forecast 2016-2026
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products in the Skin Infection Drugs Market, 2015
5.2 Skin Infection Drugs: Market Forecast 2016-2026
5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2016-2026
5.3 Leading Drugs Used in the Treatment of Skin Infections
5.3.1 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.3.2 Acquisition By Merck & Co
5.3.3 Generic Competition For Cubicin
5.3.4 Cubicin: Sales Forecast 2016-2026
5.3.5 Lifecycle Management Strategies for Cubicin
5.4 Zyvox (linezolid) – Pfizer
5.4.1 Zyvox: Historical Sales Analysis, 2010-2014
5.4.2 Zyvox: Sales Forecast 2016-2026
5.4.3 The Threats to Zyvox Sales from Competing New Drugs
5.5 Canesten (clotrimazole) – Bayer
5.5.1 Canesten: Historical Sales Analysis, 2011-2014
5.5.2 Canesten: Sales Forecast 2016-2026
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2016-2026
5.7 Bactroban (mupirocin) – GSK
5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
5.7.2 Bactroban: Sales Forecast 2015-2026
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2016-2026
5.9 Other Skin Infection Drugs
5.9.1 Dalvance (dalbavancin) – Durata Therapeutics
5.9.2 Jublia (efinaconazole) – Valeant
5.9.3 Kerydin (tavaborole) – Anacor
5.9.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.9.5 Zovirax (acyclovir) – Valeant/GSK
5.9.5.1 Valeant Acquires Zovirax In US And Canada
5.9.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.9.6 Other Skin Infection Drugs: Sales Forecast 2016-2025
5.10 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis and Forecast 2016-2026
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products in the Acne Drugs Market, 2015
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise of Combination Therapies in Acne Treatment
6.2.2 Oral Contraceptives in Treating Acne
6.2.3 The Threat of Generic Competition in the Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2026
6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2015-2026
6.4 Leading Drugs in the Acne Drugs Market
6.4.1 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.4.1.1 Epiduo: Sales Forecast 2016-2026
6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
6.4.1.3 Paediatric Approval for Epiduo
6.4.2 Solodyn (minocycline) – Valeant
6.4.2.1 Solodyn: Sales Forecast 2016-2026
6.4.2.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.4.2.3 Impax And Medicis Collaborating On Advanced Solodyn
6.4.2.4 Medicis And Lupin Settle
6.4.3 Claravis (isotretinoin) – Teva
6.4.3.1 Claravis: Sales Forecast 2016-2026
6.4.4 Aczone (dapsone) – Allergan
6.4.4.1 Aczone: Sales Forecast 2016-2026
6.4.5 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.4.5.1 Recent Generic Competition to Differin
6.4.5.2 Differin: Sales Forecast 2016-2026
6.4.5.3 Adapalene Gel to be Available OTC in the US
6.4.5.4 Federal Circuit Court Invalidates Differin Patents
6.4.6 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.4.6.1 Absorica/Epuris: Sales Forecast 2016-2025
6.4.7 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.4.7.1 Valeant’s Patent Settlement with Actavis Over Ziana
6.4.7.2 Ziana: Sales Forecast 2016-2026
6.4.8 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.4.8.1 Lifecycle Management Strategies for Doryx
6.4.8.2 Divestment Agreement with Mayne Pharma
6.4.8.3 Generic Competition for Doryx
6.4.8.4 Doryx: Sales Forecast 2016-2026
6.4.9 Other Acne Drugs
6.4.9.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.4.9.2 Amnesteem (isotretinoin) – Mylan
6.4.9.2.1 Amnesteem: Financial Analysis
6.4.9.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.4.9.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.4.9.5 Veltin (tretinoin/clindamycin) – GSK
6.4.9.6 Other Acne Drugs: Sales Forecast 2016-2026
6.5 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis and Forecast 2016-2026
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products in the Dermatitis Drugs Market, 2015
7.2 Dermatitis Drugs: Market Forecast 2016-2026
7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2016-2026
7.3 Leading Drugs in the Dermatitis Drugs Market
7.3.1 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.3.1.1 Bepanthen: Sales Forecast 2016-2026
7.3.2 Elocon (mometasone) – Merck & Co
7.3.2.1 Elocon: Sales Forecast 2016-2026
7.3.3 Protopic (tacrolimus) – LEO Pharma
7.3.3.1 Protopic Benefits from Expanded Indication
7.3.3.2 Generic Competition For Protopic
7.3.3.3 Protopic: Sales Forecast 2016-2026
7.3.4 Dermovate -GSK
7.3.4.1 Dermovate: Sales Forecast 2016-2026
7.3.5 Other Dermatitis Drugs: Sales Forecast 2016-2026
7.4 Dermatitis Drugs: Market Outlook

8. Leading National Markets for Dermatological Drugs, 2016-2026
8.1 The Dermatological Drugs Market by Region
8.1.1 The Global Distribution of Dermatological Drugs in 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares by Region, 2015-2026
8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2015-2026
8.3.1 United States: The Largest Dermatological Drugs Market
8.3.1.1 The Impact of an Expanding Medicare Coverage
8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
8.3.1.3 US Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2 The EU5 Markets: Growth Expected in Each Country
8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2015-2026
8.3.2.2 Germany
8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2016-2026
8.3.2.3 France
8.3.2.3.1 French Dermatological Drugs Market Forecast 2016-2026
8.3.2.4 UK
8.3.2.4.1 UK Dermatological Drugs Market Forecast 2016-2026
8.3.2.5 Italy
8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2016-2026
8.3.2.6 Spain
8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2016-2026
8.3.3 Japan
8.3.3.1 The Cost of Treatment in Japan
8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
8.3.3.3 Japanese Dermatological Drugs Market Forecast 2016-2026
8.3.4 China
8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
8.3.4.2 Improving Public Perception of Dermatology in China
8.4.3.3 Price Controls and the Anhui Model
8.3.4.4 Chinese Dermatological Drugs Market Forecast 2016-2026
8.3.5 India
8.3.5.1 The Effects of the Drug Prices Control Order of 2013
8.3.5.2 India’s Expansion of Healthcare Provision
8.3.5.3 Indian Dermatological Drugs Market Forecast 2016-2026
8.3.6 Brazil
8.3.6.1 The Growth in Brazil’s Healthcare Landscape
8.3.6.2 Clearer Access to Medicines in Brazil
8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2016-2026
8.3.7 Russia
8.3.7.1 Pharma2020 Strategy – Healthcare and Industry Reform
8.3.7.2 Russian Dermatological Drugs Market Forecast 2016-2026
8.3.8 Rest of the World
8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2016-2026

9. Leading Companies in the Dermatological Drugs Market, 2016-2026
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2016
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition of Galderma
9.2.2.2 Approval and Launch of Soolantra for Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson: Dermatological Drug Development
Pipeline, 2016
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2016
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2016
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2016
9.6.2 Pfizer: Dermatological Drugs Development Pipeline, 2016
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2016
9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2016

10. Dermatological Drugs: Research and Development Pipeline, 2016-2026
10.1 Innovative Products Currently in Development Will Drive Growth
10.1.1 New Technology in R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms and Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2016
10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
10.2.1.1 AMG 827 (brodalumab) – AstraZeneca/ LEO Pharma
10.2.1.2 CF101 (Piclidenoson) – Can-Fite BioPharma
10.2.1.3 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.4 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.5 MK-3222/SCH 900222 (tildrakizumab) – Merck/Sun Pharma
10.2.2 Psoriasis Drugs in Phase 2 Development
10.2.2.1 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.2 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2016
10.3.1 Drugs in Phase 3 Development for Skin Infections
10.3.1.1 Baxdela (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs in Phase 2 Development for Skin Infections
10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
10.4 Acne Drugs Development Pipeline, 2016
10.4.1 Drugs in Phase 3 Development for Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs in Phase 2 Development for Acne
10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
10.4.4 A Possible Vaccine for Acne
10.5 Dermatitis Drugs Development Pipeline, 2016
10.5.1 Drugs in Phase 3 Development for Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.2 Drugs in Phase 2 Development for Dermatitis
10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2016
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Mirvaso (brimonidine) – Galderma
10.6.1.4 Picato (ingenol mebutate) – LEO Pharma
10.6.1.5 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2016
10.6.2.1 CD5024 (ivermectin) – Galderma
10.6.2.2 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2016

11. Qualitative Analysis of the Dermatological Drugs Market, 2016-2026
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need in Dermatology
11.2.1.2 A Healthy Pipeline of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge to Treatment Design
11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors in Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation within Dermatology – Opportunity for Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement and Payment Approvals
11.2.4.2 The Rising Cost of Research and Development
11.2.4.3 Downward Pressures on Drug Prices
11.3 Porter’s Five Force Analysis of the Global Dermatological Drugs Market, 2016-2026
11.3.1 Threat of New Entrants
11.3.2 Threat of Substitutes
11.3.3 Rivalry among Competitors
11.3.4 Power of Buyers
11.3.5 Power of Suppliers

12. Conclusions
12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026
12.2 Leading Sectors in Dermatological Drugs in 2015
12.3 Leading Regions in the Dermatological Drugs Market in 2015
12.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2016-2026
12.5 What Does The Future Hold For Dermatological Drugs?

13. Glossary

List of Tables
Table 2.1 Clinical Trial Phases, 2016
Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2015
Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2020, 2020-2026, 2015-2026
Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2015, 2020 and 2026
Table 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2015
Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026
Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Table 4.5 Humira AbbVie Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Table 4.7 Stelara Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2015
Table 4.9 Enbrel Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2015
Table 4.11 Remicade Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2026
Table 4.13 Otezla Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.13 Cosentyx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 4.14 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2015
Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026
Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR(%) and CAGR(%), 2015-2026
Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR(%), 2010-2014
Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2014
Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013
Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2015-2026
Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.1 Top Drugs In The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2015
Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2015, 2020 and 2026
Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2015-2026
Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2015-2026
Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2015
Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2015, 2020, 2026
Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2015-2026
Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2015
Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2026
Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2015-2020, 2020-2026, and 2015-2026
Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2015, 2020 and 2026
Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2015
Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2015, 2020 and 2026
Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.13 The French Dermatological Drugs Market Forecast: Revenue($bn, AGR (%)and CAGR (%), 2015-2026
Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2015-2026
Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2015-2026
Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
Table 9.1 Galderma: Company Overview, 2016
Table 9.2 Johnson & Johnson: Company Overview, 2016
Table 9.3 AbbVie: Company Overview, 2016
Table 9.4 GlaxoSmithKline: Company Overview, 2016
Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016
Table 9.6 Pfizer: Company Overview, 2016
Table 9.7 LEO Pharma: Company Overview, 2016
Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016
Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016
Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016
Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016
Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2015-2025
Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2015, 2020 and 2026
Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn) and Market Shares (%), 2015
Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2015, 2020 and 2026
Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2015, 2020, 2026

List of Figures
Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2016
Figure 2.1 Anatomy of Human Skin
Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2015
Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2015-2026
Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2020
Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2020-2026
Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2015-2026
Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2015
Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2020
Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2026
Figure 4.1 Top Drugs In The Psoriasis Drugs Market: Revenue ($bn), 2015
Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2015
Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2020
Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2026
Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-2015
Figure 4.7 Humira AbbVie Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Figure 4.9 Stelara Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015
Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
Figure 4.13 Remicade Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2026
Figure 4.15 Otezla Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.16 Cosentyx Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2015
Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2015
Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2020
Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2026
Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2015-2026
Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014
Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013
Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-20265
Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2015
Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2015
Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2020
Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2026
Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.1 Top Drugs In The Dermatitis Drugs Market: Revenue ($bn), 2015
Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2015
Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2020
Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2026
Figure 7.6 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2015
Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2015
Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2020
Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2026
Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2015-2026
Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2015
Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2015-2026
Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2015
Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2020
Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2026
Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2014-2025
Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
Figure 11.1 Porter’s Five Force Analysis of the Dermatological Drugs Market, 2016
Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2015, 2018, 2020, 2026
Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2015
Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2015, 2020, 2026

★調査レポート[皮膚科治療薬の世界市場予測2016-2026]販売に関する免責事項
★調査レポート[皮膚科治療薬の世界市場予測2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆